Abstract
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.
Lingua originale | English |
---|---|
pagine (da-a) | e1483-e1487 |
Rivista | Clinical Gastroenterology and Hepatology |
Volume | 20 |
DOI | |
Stato di pubblicazione | Pubblicato - 2022 |
Keywords
- INFLAMMATORY BOWEL DISEASE
- VEDOLIZUMAB